Topic Editors

Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung 20401, Taiwan
School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan

Advance in Cancer Pharmacoepidemiology

Abstract submission deadline
20 December 2024
Manuscript submission deadline
20 February 2025
Viewed by
4091

Topic Information

Dear Colleagues,

Cancer is a leading cause of mortality worldwide, and in recent years, novel treatments have been developed and approved that have improved the overall survival rate and quality of life of patients.

Cancer pharmacoepidemiology focuses on the real-world use, effects, and outcomes of cancer therapies, including chemotherapy, immunotherapy, targeted therapy, and supportive care medications, in large patient populations.

We are inviting you to contribute high-quality research relating to cancer pharmacoepidemiology that addresses research questions using innovative methods, for example, large-scale observational studies, target trial emulation, and systematic review with meta-analysis.

Topics of interest include, but are not limited to, the following:

  • The real-world effectiveness and safety of cancer therapies;
  • Cancer therapy patterns of use;
  • The comparative effectiveness of cancer therapies;
  • Health disparities in the use and outcomes of cancer therapies;
  • The impact of novel cancer therapies on healthcare utilization and costs;
  • Methodological papers to improve the study validity of cancer pharmacoepidemiology.

We invite submissions from researchers, clinicians, and other stakeholders involved in cancer care worldwide. All submitted papers will undergo a timely and rigorous peer-review process.

We look forward to receiving your submissions and advancing our understanding of cancer pharmacoepidemiology.

Dr. Shih-Chieh Shao
Dr. Edward Chia-Cheng Lai
Topic Editors

Keywords

  • pharmacoepidemiology
  • methodology
  • observational study
  • meta-analysis
  • cancer
  • oncology
  • drug safety
  • drug effectiveness
  • real-world evidence

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cancers
cancers
5.2 7.4 2009 17.9 Days CHF 2900 Submit
Healthcare
healthcare
2.8 2.7 2013 19.5 Days CHF 2700 Submit
Pharmaceuticals
pharmaceuticals
4.6 4.7 2004 14.6 Days CHF 2900 Submit
Pharmaceutics
pharmaceutics
5.4 6.9 2009 14.2 Days CHF 2900 Submit
Pharmacoepidemiology
pharmacoepidemiology
- - 2022 34.2 Days CHF 1000 Submit

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (2 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
32 pages, 4669 KiB  
Review
Research Progress of Metal Anticancer Drugs
by Yun Bai, Gerile Aodeng, Lu Ga, Wenfeng Hai and Jun Ai
Pharmaceutics 2023, 15(12), 2750; https://doi.org/10.3390/pharmaceutics15122750 - 11 Dec 2023
Cited by 2 | Viewed by 1728
Abstract
Cancer treatments, including traditional chemotherapy, have failed to cure human malignancies. The main reasons for the failure of these treatments are the inevitable drug resistance and serious side effects. In clinical treatment, only 5 percent of the 50 percent of cancer patients who [...] Read more.
Cancer treatments, including traditional chemotherapy, have failed to cure human malignancies. The main reasons for the failure of these treatments are the inevitable drug resistance and serious side effects. In clinical treatment, only 5 percent of the 50 percent of cancer patients who are able to receive conventional chemotherapy survive. Because of these factors, being able to develop a drug and treatment that can target only cancer cells without affecting normal cells remains a big challenge. Since the special properties of cisplatin in the treatment of malignant tumors were accidentally discovered in the last century, metal anticancer drugs have become a research hotspot. Metal anticancer drugs have unique pharmaceutical properties, such as ruthenium metal drugs with their high selectivity, low toxicity, easy absorption by tumor tissue, excretion, and so on. In recent years, efficient and low-toxicity metal antitumor complexes have been synthesized. In this paper, the scientific literature on platinum (Pt), ruthenium (Ru), iridium (Ir), gold (Au), and other anticancer complexes was reviewed by referring to a large amount of relevant literature at home and abroad. Full article
(This article belongs to the Topic Advance in Cancer Pharmacoepidemiology)
Show Figures

Figure 1

13 pages, 820 KiB  
Article
Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System
by Vera Martins, Mafalda Jesus, Luísa Pereira, Cristina Monteiro, Ana Paula Duarte and Manuel Morgado
Pharmaceuticals 2023, 16(10), 1340; https://doi.org/10.3390/ph16101340 - 22 Sep 2023
Viewed by 1345
Abstract
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a recent targeted therapy approved for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. Abemaciclib, palbociclib and ribociclib demonstrated great efficacy and safety during clinical studies. However, [...] Read more.
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a recent targeted therapy approved for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. Abemaciclib, palbociclib and ribociclib demonstrated great efficacy and safety during clinical studies. However, differences in their adverse-event profiles have been observed. This work aims to describe the suspected adverse drug reactions (ADRs), such as leukopenia and thrombocytopenia, reported for each CDK4/6 inhibitor in the EudraVigilance (EV) database. Data on individual case safety reports (ICSRs) were obtained by accessing the European spontaneous reporting system via the EV website. Information on concomitant drug therapy, including fulvestrant, letrozole, anastrozole and exemestane, was also analyzed. A total of 1611 ICSRs were collected from the EV database. Most reports of palbociclib and ribociclib were classified as serious cases for both suspected leukopenia and thrombocytopenia ADRs. However, most patients had their leukopenia and thrombocytopenia recovered/resolved. On the contrary, reports of abemaciclib were mostly characterized as non-serious cases. Abemaciclib and palbociclib were often combined with fulvestrant, while ribociclib was generally associated with letrozole. Pharmacovigilance studies are crucial for the early identification of potential ADRs and to better differentiate the toxicity profile of the different CDK4/6 inhibitors, particularly in a real-world setting. Full article
(This article belongs to the Topic Advance in Cancer Pharmacoepidemiology)
Show Figures

Figure 1

Back to TopTop